Are NICE recommendations for cardiovascular and diabetes prevention appropriate in moderate-to-severe frailty?

Background: UK guidance increasingly promotes disease-focused prevention strategies. The 2026 National Institute for Health and Care Excellence (NICE) guideline for type 2 diabetes mellitus (T2DM) advocates early initiation of metformin and sodium–glucose cotransporter-2 (SGLT2) inhibitors, while recent NICE cardiovascular prevention guidance supports intensive blood pressure and lipid lowering. In contrast, British Geriatrics Society (BGS) pragmatic prescribing guidance recommends individualised targets and treatment deintensification in people living with moderate-to-severe frailty. Whether aggressive cardiometabolic prevention improves outcomes in this population remains uncertain.

Aim: To evaluate whether cardiovascular and T2DM prevention strategies improve clinical outcomes in adults with moderate-to-severe frailty.

Methods: A systematic search of Embase, MEDLINE, CENTRAL and Scopus identified cohort studies, case-control studies and randomized controlled trials evaluating T2DM and cardiovascular prevention strategies in adults aged ≥65 years with moderate-to-severe frailty.

Results: Post-hoc analyses of major cardiovascular trials demonstrated preserved benefit from intensive blood pressure reduction across frailty strata. In SPRINT, intensive systolic blood pressure control (<120 mmHg versus <140 mmHg) reduced composite cardiovascular outcomes, with no significant interaction according to frailty status. Frailty analyses of HYVET and ESPRIT similarly reported comparable cardiovascular outcomes irrespective of frailty. In ADVANCE, intensive glucose and blood pressure control reduced major vascular events by 9%, although benefits diminished with increasing frailty. The ACCORD older subgroup showed no mortality benefit from intensive glycaemic control and reported increased severe hypoglycaemia. Observational studies suggest that SGLT2 inhibitors remain effective in frail populations, reducing heart failure hospitalisation and all-cause mortality in patients with heart failure and T2DM.

Conclusion: Current evidence only partially supports disease-centred NICE recommendations in people living with moderate-to-severe frailty. Although cardiovascular benefits appear to persist in selected frail populations, the risks of polypharmacy, falls and treatment burden necessitate a more individualised, frailty-centred approach.